Information Provided By: 
Fly News Breaks for September 13, 2018
HOLX
Sep 13, 2018 | 06:22 EDT
BofA/Merrill analyst Derik de Bruin downgraded Hologic (HOLX) to Neutral from Buy and lowered its price target to $42 from $47 following last night's 8-K filing updating the impact from the Vitalia recall and now expects a $15M hit and lowered sales of MonaLisa Touch. de Bruin is concerned about the ongoing lack of visibility, the continued headwinds, and uncertainty surrounding the Quest Diagnostics (DGX) contract renewal.
News For HOLX From the Last 2 Days
There are no results for your query HOLX
